Because melatonin shows a broad synergistic benefit with chemotherapies, the therapeutic efficacy of melatonin as an adjuvant, in combination with immunotherapies such as anti-PD1 or anti-PD-L1, envisions a promising approach for lung cancer treatment, and future research is warranted to investigate. This evidence concerns the gene CD274 and lung carcinoma.